Markets:

Overview

News

Currencies

International

Treasuries

COMPASS Pathways Plc - American Depository Shares (NQ:CMPS)

7.310 -0.040 (-0.54%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2 3 4 5 6 7 8 9

...

30 31 Next >

CMPS Stock Climbs 5% In Premarket After FDA Clears PTSD Trial Path ↗

January 07, 2026

Via Stocktwits

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

January 07, 2026

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360

January 06, 2026

From Compass Pathfinder Limited

Via Business Wire

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Earnings Scheduled For July 31, 2025 ↗

July 31, 2025

Via Benzinga

Psychedelics Break Out Of The Fringe Under RFK Jr’s 2025 Reset — But Did MNMD Or CMPS Own The Year? ↗

December 24, 2025

Regulatory thaw, political backing, and late-stage data are propelling psychedelic drugmakers into the biotech spotlight — with Compass Pathways and Mind Medicine leading the charge.

Via Stocktwits

Topics ETFs

Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

December 09, 2025

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways to Participate in Two Investor Conferences in December

November 20, 2025

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways to Participate in Stifel 2025 Healthcare Conference

November 05, 2025

From Compass Pathfinder Limited

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 04, 2025

Via Benzinga

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months

November 04, 2025

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors

October 29, 2025

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

October 28, 2025

From Compass Pathfinder Limited

Via Business Wire

Design Therapeutics Appoints Justin Gover to Board of Directors

September 10, 2025

From Design Therapeutics, Inc.

Via GlobeNewswire

Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder

September 02, 2025

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways to Participate in Four Investor Conferences in September

August 27, 2025

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways to Participate in Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 in Boston, MA

August 05, 2025

From Compass Pathfinder Limited

Via Business Wire

Compass (CMPS) Q2 Loss Improves 27% ↗

August 01, 2025

Via The Motley Fool

Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights

July 31, 2025

From Compass Pathfinder

Via Business Wire

Compass Pathways Appoints Justin Gover to Board of Directors

July 29, 2025

From Compass Pathfinder Limited

Via Business Wire

Compass Pathways to Announce Second Quarter Financial Results on July 31, 2025

July 22, 2025

From Compass Pathfinder Limited

Via Business Wire

These 2 Stocks Could More Than Double Your Money, According to Wall Street. Is It Time to Buy? ↗

July 20, 2025

Via The Motley Fool

Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET

July 10, 2025

From Compass Pathfinder Limited

Via Business Wire

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

July 01, 2025

From FN Media Group LLC

Via GlobeNewswire

Stifel Says Compass Pathways Selloff 'Significantly Overdone' After Psilocybin Trial Data ↗

June 24, 2025

The company is also conducting a second Phase 3 study evaluating the effects of two doses of COMP360 given three weeks apart.

Via Stocktwits

Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032

July 01, 2025

EQNX::TICKER_START (NYSE:CYBN),(NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:SAGE),(NASDAQ:MNMD),(NASDAQ:ATAI),(NEO:MMED) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

What's going on in today's session ↗

June 23, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

Compass Pathways Stock Is Plunging Today: What's Going On? ↗

June 23, 2025

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in the ongoing Phase 3 COMP005 trial, but results may have not met lofty...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 23, 2025

Via Benzinga

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts ↗

June 23, 2025

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

30 31 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.